Aim: To investigate real-world chimeric antigen receptor (CAR) T-cell therapy treatment patterns. Patient & methods: Relapsed/refractory large B-cell lymphoma patients who received CAR T-cell therapy were identified. Patient characteristics, setting of CAR T-cell infusion, incidence of CAR T-cell therapy-associated adverse events and healthcare resource utilization were assessed. Results: Of 1175 patients, 83% were infused inpatient. Within three days postinfusion, inpatient-infused patients had a significantly higher risk of CAR T-associated adverse events (hazard ratio: 2.67; 95% CI: 2.09–3.42) compared with outpatient-infused patients. By day 30, 67% of outpatient-infused patients were hospitalized at least once. Conclusion: These findings suggest that physicians were able to select lower-risk patients for outpatient infusion, but postinfusion hospitalizations still occur.

Plain language summary – Real-world treatment patterns after chimeric antigen receptor T-cell therapy among patients with relapsed or refractory large B-cell lymphoma

This study tracks outcomes in patients with relapsed/refractory large B-cell lymphoma who received chimeric antigen receptor (CAR) T-cell therapy between 2017 and 2020. The authors used the Anlitiks All-Payor Claims (AAPC) database, which includes insurance claims of patients covered through Medicare, Medicaid or commercial insurance plans. AAPC includes over 80% of insured patients in the USA healthcare system. The study describes where patients received CAR T-cell therapy (inpatient/outpatient), rates of adverse events potentially related to CAR T-cell treatment and how much healthcare the patients received. In the 3 days after receiving CAR T-cell therapy, rates of CAR T-associated adverse events were significantly higher in patients who received CAR T-cell therapy in the inpatient setting, compared with outpatients. The findings suggest that lower-risk patients may receive CAR T-cell therapy as outpatients, but that most outpatient-infused patients will still require inpatient care.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. National Cancer Institute SEER Program. Cancer stat facts: NHL–diffuse large B-cell lymphoma (DLBCL) (2022). https://seer.cancer.gov/statfacts/html/dlbcl.html
Google Scholar
2. Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematol. Am. Soc. Hematol. Educ. Program 2011(1), 498–505 (2011).
MedlineGoogle Scholar
3. Seshadri T, Kuruvilla J, Crump M, Keating A. Salvage therapy for relapsed/refractory diffuse large B cell lymphoma. Biol. Blood Marrow Transplant. 14(3), 259–267 (2008).
Medline CASGoogle Scholar
4. Zhang J, Medeiros LJ, Young KH. Cancer immunotherapy in diffuse large B-cell lymphoma. Front. Oncol. 8, 351 (2018).
Medline CASGoogle Scholar
5. Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: r-CHOP failure-what to do? Hematol. Am. Soc. Hematol. Educ. Program 2016(1), 366–378 (2016). • To date, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is the standard treatment option for patients with large B-cell lymphoma (LBCL). Nevertheless, roughly 30–50% of patients experience treatment failure with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. This article highlights the unmet need for improved treatment options for relapsed or refractory (RR) LBCL patients.
MedlineGoogle Scholar
6. Huntington SK, Keshishian A, Xie L, Onur B, McGuire M. Evaluating the economic burden and health care utilization following first-line therapy for diffuse large B-cell lymphoma patients in the US Medicare population. Blood 128(22), 3574–3574 (2016).
Google Scholar
7. Purdum A, Tieu R, Reddy SR, Broder MS. Direct costs associated with relapsed diffuse large B-cell lymphoma therapies. Oncologist 24(9), 1229–1236 (2019).
Medline CASGoogle Scholar
8. Crump M, Neelapu SS, Farooq U et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16), 1800–1808 (2017).
Medline CASGoogle Scholar
9. National Comprehensive Cancer Center Clinical Practice Guidelines in Oncology (NCCN Guidelines): B-Cell Lymphomas. National Comprehensive Cancer Network (2022). https://www.nccn.org/guidelines/category_1
Google Scholar
10. Epperla N, Hamadani M. Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: current controversies and advances. Hematol. Oncol. Stem Cell Ther. 10(4), 277–284 (2017).
Medline CASGoogle Scholar
11. Huntington S, Keshishian A, Mcguire M, Xie L, Baser O. Costs of relapsed diffuse large B-cell lymphoma among Medicare patients. Leuk. Lymphoma 59(12), 2880–2887 (2018).
MedlineGoogle Scholar
12. Gisselbrecht C, Glass B, Mounier N et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J. Clin. Oncol. 28(27), 4184–4190 (2010).
MedlineGoogle Scholar
13. Neelapu SS, Locke FL, Bartlett NL et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377(26), 2531–2544 (2017).
Medline CASGoogle Scholar
14. Schuster SJ, Bishop MR, Tam CS et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380(1), 45–56 (2019).
Medline CASGoogle Scholar
15. Locke FL, Neelapu SS, Bartlett NL et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol. Ther. 25(1), 285–295 (2017).
Medline CASGoogle Scholar
16. National Cancer Institute. FDA approves second CAR T-cell therapy for lymphoma 2018 (2022). www.cancer.gov/news-events/cancer-currents-blog/2018/tisagenlecleucel-fda-lymphoma
Google Scholar
17. Van Den Neste E, Schmitz N, Mounier N et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 52(2), 216–221 (2017). • Outcomes for RR LBCL patients relapsing after second-line high-dose chemotherapy followed by autologous transplant are poor. Results from the CORAL study are highlighted in this article. The CORAL study served as the benchmark for trials of chimeric antigen receptor (CAR) T-cell therapy and other novel agents.
MedlineGoogle Scholar
18. Locke FL, Ghobadi A, Jacobson CA et al. Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma. J. Clin. Oncol. 36(Suppl. 15), 3003–3003 (2018).
Google Scholar
19. Chavez JC, Bachmeier C, Kharfan-Dabaja MA. CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther. Adv. Hematol. 10, 2040620719841581 (2019).
Google Scholar
20. Chow VA, Shadman M, Gopal AK. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Blood 132(8), 777–781 (2018).
Medline CASGoogle Scholar
21. Hopfinger G, Jäger U, Worel N. CAR-T cell therapy in diffuse large B cell lymphoma: hype and hope. Hemasphere 3(2), e185 (2019). • This review highlights results from a large phase II CAR T-cell therapy trial, with a focus on adverse events (AE) that require inpatient care. Given the AE profile of CAR T-cell therapies and the need to monitor patients in the short term after CAR T-cell infusion, these therapies have been primarily administered in the inpatient setting until recently. This article is relevant as clinicians are gaining increasing experience with CAR T-cell treatment options and the potential consequences of their use.
MedlineGoogle Scholar
22. Crump M, Neelapu SS, Farooq U et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 131(5), 587–588 (2018).
Medline CASGoogle Scholar
23. Abramson JS, Palomba ML, Gordon LI et al. High durable CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (TRANSCEND NHL 001): defined composition allows for dose-finding and definition of pivotal cohort. Blood 130(Suppl. 1), 581–581 (2017).
MedlineGoogle Scholar
24. Neelapu SS, Tummala S, Kebriaei P et al. Chimeric antigen receptor T-cell therapy–assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15(1), 47–62 (2018).
Medline CASGoogle Scholar
25. Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J. Clin. 60(6), 393–408 (2010).
MedlineGoogle Scholar
26. Kuehn BM. The promise and challenges of CAR-T gene therapy. JAMA 318(22), 2167–2169 (2017).
MedlineGoogle Scholar
27. The ASCO Post Staff. Treatment centers authorized to administer CAR T-cell therapy. ASCO Post (2022). https://ascopost.com/issues/may-25-2018/treatment-centers-authorized-to-administer-car-t-cell-therapy/
Google Scholar
28. Smith S, Essell JH. Evolving the delivery of CAR T-cell therapies to the outpatient setting. J. Clin. Pathw. 4(8), 42–47 (2018). • This article highlights the patient journey and the need for increased access to CAR T-cell therapy for RR LBCL patients who have exhausted all other treatment options. The review adds to the body of evidence that suggests an increased interest in outpatient CAR T-cell therapy treatment.
Google Scholar
29. The ASCO Post. ASH 2017: JULIET Trial: 6-month analysis of tisagenlecleucel in relapsed/refractory DLBCL shows sustained responses. ASCO Post, 30th December (2022). https://ascopost.com/News.aspx?id=58349
Google Scholar
30. Graff TM, Singavi AK, Schmidt W et al. Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. Bone Marrow Transplant. 50(7), 947–953 (2015).
Medline CASGoogle Scholar
31. Lion J, Henderson M, Malbon A, Bergman A, Come S. Case mix and charges for inpatient and outpatient chemotherapy. Health Care Financ. Rev. 8(4), 65–71 (1987).
Medline CASGoogle Scholar
32. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med. Care 36(1), 8–27 (1998).
Medline CASGoogle Scholar
33. Lee DW, Santomasso BD, Locke FL et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25(4), 625–638 (2019).
Medline CASGoogle Scholar
34. Broder MS, Ma Q, Yan T et al. Economic burden of neurologic toxicities associated with treatment of patients with relapsed or refractory diffuse large B-cell lymphoma in the United States. Am. Health Drug Benefits 13(5), 192–199 (2020). •• This retrospective claims-based analysis evaluated healthcare costs associated with CAR T-associated AEs. Additional research assessing the clinical and economic burden associated with CAR T-cell therapies is needed to help better inform therapeutic decision-making.
MedlineGoogle Scholar
35. Palomba ML, Jun MP, Lymp J et al. Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials. Leuk. Lymphoma 62(9), 2169–2176 (2021). •• This retrospective study evaluated healthcare resource utilization and costs following CAR T-cell therapy. Results were stratified by setting of CAR T-cell infusion; lower healthcare resource utilization rates were observed in outpatient settings. This study is important because it suggests that extending CAR T-cell therapy to the outpatient setting may increase access to treatment while also improving resource allocation, thereby reducing healthcare costs.
Medline CASGoogle Scholar
36. Godwin JE, Mattar B, Maris M et al. OUTREACH: results from a phase 2 study of lisocabtagene maraleucel (liso-cel) administered as inpatient (Inpt) or outpatient (Outpt) treatment in the nonuniversity setting in patients (Pts) with R/R large B-cell lymphoma (LBCL). Blood 138(Suppl. 1), 1762–1762 (2021).
Google Scholar
37. Borogovac A, Keruakous A, Bycko M et al. Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center. Bone Marrow Transplant. 57(6), 1025–1027 (2022).
MedlineGoogle Scholar
38. Myers GD, Michael RV, Andre G, Richard TM. Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia. J. Immunother. Cancer 9(4), e002056 (2021).
MedlineGoogle Scholar
39. Knight JM, Hackett E, Szabo A et al. Associations between socioeconomic status and bispecific LV20.19 CAR T-cell therapy outcomes. Haematologica 108(2), 588–593 (2023).
Medline CASGoogle Scholar
40. Seyedin r, Snider JT, RajagopalanK et al. Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma. American Society for Hematology Annual Meeting (2021).
Google Scholar

Vol. 19, No. 22

Supplemental Materials

Metrics

Downloaded 76 times

History

Received 17 February 2023

Accepted 30 June 2023

Published online 14 August 2023

Published in print July 2023

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/fon-2023-0140

Author contributions

All authors made substantive contributions to the study design and results interpretation for this work. JT Snider, R Seyedin, K Rajagopalan and SW Wade guided and/or conducted the data analysis and U Gergis provided clinical expertise throughout the study. R Seyedin developed the initial draft manuscript and all authors reviewed and provided critical revisions, along with approval of the final manuscript.

Financial & competing interests disclosure

Funding for this work was provided by Kite, a Gilead company. U Gergis serves on the speaker bureau and reports consultancy for Kite/Gilead. SW Wade, K Rajagopalan and R Seyedin report consultancy for Kite/Gilead. JT Snider reports employment and stock options from Kite/Gilead. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this work.

Previous presentation

Selected results from this study were presented at the American Society for Hematology 2021 Annual Meeting [40].

PDF download

Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma

Abstract

Plain language summary – Real-world treatment patterns after chimeric antigen receptor T-cell therapy among patients with relapsed or refractory large B-cell lymphoma

References